Assessment of problematic severe asthma in children


*Members of the Global Allergy and Asthma European Network GA²LEN

Affiliations

K. Lødrup Carlsen: Department of Paediatrics, Oslo University Hospital and the Faculty of Medicine, University of Oslo, Norway. G. Hedlin: Dept. of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden. A. Bush: Department of Respiratory Paediatrics, Royal Brompton Hospital, London, UK. G. Wennergren: Department of Paediatrics, University of Gothenburg, Queen Silvia Children's Hospital, Gothenburg, Sweden. F.M. de Benedictis: Department of Paediatrics, Salesi Children's Hospital, Ancona, Italy. J.C. De Jongste: Department of Paediatrics, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands. E. Baraldi: Department of Pediatrics, University of Padova, School of Medicine, Padova, Italy. C. Pedroletti: Dept. of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden. A. Barbato: Department of Paediatrics, University of Padova, Padova, Italy. K. Malmström: Department of Allergy, Helsinki University Central Hospital, Helsinki, Finland. P. Pohunek: Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. S. Pedersen: University of Southern Denmark, Department of Paediatrics, Kolding Hospital, Kolding, Denmark. G.L. Piacentini: Department of Paediatrics, University of Verona, Verona, Italy. R.J.M. Middelveld: The Centre for Allergy Research, Institute of Environmental Medicine,
Karolinska Institutet, Stockholm, Sweden. K.H. Carlsen: Department of Paediatrics, Oslo University Hospital, and the Faculty of Medicine, University of Oslo, Norway.

**Corresponding author:**

Prof. Karin C. Lødrup Carlsen
Department of Paediatrics, Women and Child’s Clinic
Oslo University Hospital and the
University of Oslo
NO-0407 Oslo
Norway
Telephone: 22 11 87 65    Fax: 22 11 86 63    e-mail: k.c.l.carlsen@medisin.uio.no

**Total word count:** 3941 + abstract 130 + one table

**Final draft, June 11th 2010**
ABSTRACT

Assessment of problematic severe asthma in children should be done in a step-wise manner to ensure an optimal approach. A four-step assessment scheme is proposed. First, a full diagnostic work-up is performed to exclude other diseases which mimic asthma.; next a multi-disciplinary assessment to identify issues that may need attention, including co-morbidities. Thirdly, the pattern of inflammation is assessed, and finally steroid responsiveness is documented. Based upon these four steps an optimal individualised treatment plan is developed. The many gaps in our current knowledge in all these steps are highlighted, and recommendations for current clinical practice and future research are made. The lack of good data and the heterogeneity of problematic severe asthma still limit our ability to optimise the management on an individual basis in this small, but challenging group of patients.

KEYWORDS

Asthma, child, severe, diagnostics
INTRODUCTION

Although the majority of children with asthma respond well to standard therapy, a significant proportion still have problematic, severe disease that is not controlled with conventional management. A birth cohort identified 4.5% of the asthmatic children with “severe asthma”, whereas 39^2 - 55^3% of children with problematic severe asthma had “difficult to treat” asthma. A recent paper, which discussed definitions, classifications and age-related presentation of problematic severe asthma in childhood, suggested which asthmatic children warranted further investigation and outlined triggers of asthma exacerbations. It was emphasized that many children may have factors apart from the underlying severity of asthma that contribute to their severe disease, including co-morbidities, socioeconomic problems, adverse environmental exposures (such as tobacco smoke, relevant allergens and other harmful factors), psychological problems and especially poor adherence to treatment.

Age is relevant not only for the presentation of disease and the underlying pathophysiology, but also for the way the child can be assessed. The present paper focuses on age-appropriate assessment methods for which there is a scientific basis, and reports on a step-wise approach to assess diagnostic possibilities, airway inflammation and therapeutic responses to corticosteroids (figure 1). Essentially, these steps lead to the child being placed in one of four categories: wrong diagnosis (“Not asthma”); asthma with significant co-morbidities which need to be addressed (“Asthma plus”); asthma which is not responding to treatment because the basics have not been got right (“Difficult asthma”); and true “Severe, therapy-resistant asthma”. It is this last group that would be candidate for the expensive and potentially hazardous cytokine specific therapies. Treatment of this last group will be covered in a further review. Finally, knowledge gaps will be discussed.

STEP 1: EXCLUDE WRONG DIAGNOSIS
It is crucial to get the diagnosis right. The most important differential diagnoses and their relevance vary geographically (for example tuberculosis and cystic fibrosis) and particular diagnostic vigilance should be exercised if the child is non-atopic. Tests include, but are not limited to: sweat test and genotyping for cystic fibrosis; nasal nitric oxide and biopsy for primary ciliary dyskinesia; High-Resolution Computed Tomography (HRCT) scan for interstitial lung disease, bronchiectasis and airway malformations; and other relevant tests for systemic disease. Furthermore, a history of severe, persistent, unusual or recurrent infections should prompt immunological investigations including serum IgG (including subclasses), IgM and IgA, evaluation of antibody response to common antigens and vaccines, and HIV testing. Studies of granulocyte and T-cell function may be warranted. Multi-system conditions such as Churg-Strauss syndrome, or Wegener’s granulomatosis, should be considered. A focused approach guided by history and physical examination is more appropriate than slavishly doing every possible test on all children.

- **Clinical recommendation**: a detailed re-assessment of the diagnosis should be performed in all patients whose asthma does not appear to be responding to treatment. What test to perform should be based upon local disease prevalences, but in all patients a minimum tests to include are a chest X-ray, immunoglobulins and a sweat test.

**STEP 2: FULL MULTI-DISCIPLINARY ASSESSMENT**

*In the patient*

**Lung function**

Spirometry and acute bronchodilator reversibility will usually have been part of Step 1 and certainly, failure to demonstrate variable airflow obstruction over time or with treatment should lead to consideration of alternative diagnoses. Although reduced lung function values
are commonly included in asthma classifications in childhood, the scientific rationale for this is questionable. The requirement for a reduction in first second forced expired volume (FEV\textsubscript{1}) as a diagnostic criterion for severe asthma in children\textsuperscript{5,6} or in management guidelines\textsuperscript{7,8} will exclude the majority of children who meet the other diagnostic criteria\textsuperscript{9}. Children with problematic severe asthma have less impairment of lung function than adults\textsuperscript{10-12}. Severe exacerbations appear to be associated with a more rapid decline in lung function in children but not adolescents\textsuperscript{13}. This may be attenuated by treatment with inhaled corticosteroids\textsuperscript{13}. Since children with severe asthma may have preserved FEV\textsubscript{1}, post bronchodilator mid-expiratory flow rates such as Forced Expiratory Flow (FEF\textsubscript{25-75} or FEF\textsubscript{50})\textsuperscript{10,14,15} or the FEV/FVC ratio\textsuperscript{12,14} may be more sensitive for (better reflecting bronchial obstruction) severe asthma than FEV\textsubscript{1}\textsuperscript{12,14}. However, many children with genuine severe, therapy resistant asthma have normal spirometry when asymptomatic. Nonetheless, spirometry is an important part of the assessment, using relevant reference values\textsuperscript{16,17}, since reduced FEV\textsubscript{1} strongly supports problematic severe asthma\textsuperscript{12}. One thrust of the work-up is to identify children with persistent airflow limitation. However, for this condition there is no generally accepted definition in paediatrics and we suggest that children who, despite an adequate trial of systemic steroids (although we note that there is no uniformly agreed definition in paediatrics as to what is an adequate dose or duration) and acute response to bronchodilator, have an FEV\textsubscript{1} of more than 1.96 Z-scores below the mean should be considered to have persistent airflow limitation.

Measures of airways resistance are not routinely performed, and their added value to spirometry in assessment of disease severity is not demonstrated. Furthermore, measures are technically more challenging than is spirometry and interpretation of measures are less standardised than is the case for spirometry. Thus, at present such measures are more useful in a research
Clinical recommendation: Spirometry and measurement of the immediate response to a bronchodilator should be performed (if age-appropriate) in all children with problematic severe asthma

Research recommendation: More longitudinal data should be collected on lung function growth in children with problematic severe asthma. Assessment of trapped air and other more sophisticated tests of lung function need scientific evaluation in problematic severe asthma and may be useful for evaluation of therapy response and peripheral airflow obstruction.

Bronchial hyperresponsiveness

A bronchial challenge test may already have been performed as part of Step 1 and if a challenge test is negative in a child thought to be very symptomatic due to asthma, the diagnosis should be questioned. The association between increased bronchial hyperresponsiveness (BHR) and severe asthma was recently supported by a specificity of 90% of provocation dose of methacholine causing a 20% fall in FEV1 PD_{20}methacholine of less than 0.2 μmol (< 1 micromol in the original paper) to discriminate between children with severe versus mild to moderate asthma. The increased BHR in children with more severe forms of asthma is particularly important in relation to exercise-induced bronchoconstriction (EIB) and to lack of asthma control. The indirect methods including standardised exercise test, cold air inhalation with exercise, eucapnic voluntary hyperventilation (EVH) or inhaled mannitol have different sensitivity and specificity for the diagnosis of asthma, as well as in response to therapy. The indirect tests, like exercise and mannitol inhalation are usually highly specific, but with low sensitivity for asthma, although their associations with problematic severe asthma in childhood is not known. Treatment guided by BHR measures was found to improve childhood asthma control in
some\textsuperscript{28 29}, but not all studies\textsuperscript{30}. Although challenge tests in children with problematic severe asthma are not part of the routine evaluation in many places, they are important measures of asthma control\textsuperscript{9 31 32} and should be performed in accordance with standardised protocols under close observation. In some patients however, such tests cannot be performed due to bronchial obstruction or other contra-indications.

- **Clinical recommendation**: Assessing BHR (if baseline conditions allow) and exercise limitation should be part of routine assessment in problematic severe asthma whenever possible

- **Research recommendation**: Establishing the value of EIB-testing and other direct and indirect measures of BHR in differentiating severe from less severe forms of asthma, as well as their role in monitoring problematic severe asthma, requires further studies.

**Allergy**

The risk of severe chronic asthma increases with multiple sensitizations and high total IgE levels\textsuperscript{33 34}. In fatal childhood asthma, allergens have been linked to the cause of death. This particularly relates to food allergens like peanut, but also to airborne allergen exposure such as animal dander, moulds\textsuperscript{35} and high pollen levels in combination with physical exercise\textsuperscript{36}. Hence, a thorough evaluation of possible allergies and their relevance to clinical disease and severity is mandatory in a child presenting with problematic severe asthma. The child’s history is the most important part of that evaluation but needs to be complemented with further investigations\textsuperscript{37}. Allergy testing should be considered in problematic severe asthma for the following indications: (a) to guide allergen avoidance measures; (b) if treatment with omalizumab is considered (this should be preceded by all reasonable attempts to exclude environmental allergens); (c) to identify the rare child with severe asthma and fungal
sensitization who may need avoidance measures and antifungal therapy; (d) if allergic bronchopulmonary aspergillosis (ABPA) is a possibility; and (e) to identify the rare non-atopic asthmatic, in whom the possibility of another diagnosis should be reconsidered. The standard methods, skin prick testing and RAST tests, may give discordant results and should probably both be performed. Newly-developed methods enable analysis of multiple antigen components that may prove helpful in differentiating between allergies that can cause life-threatening asthma and sensitisations of less importance for the disease severity.

Assessing the impact of allergen avoidance in any child with problematic severe asthma should be part of the clinical investigation. The value of house dust mite avoidance for asthmatic patients has been questioned, but several lines of evidence suggest it may be useful in severe asthma. Firstly, low dose allergen exposure, insufficient to cause acute deterioration, may lead to steroid resistance by an interleukin (IL)-2 and IL-4 dependent mechanism. Secondly, the combination of viral infection, allergen sensitization and high levels of exposure to that allergen in the home are predictive of severe exacerbations (REF), and of these factors only allergen exposure is amenable to intervention. It is likely that the expense and inconvenience of allergen avoidance is more likely to be acceptable in children with severe asthma. In summary, we believe there is sufficient evidence to recommend avoidance of aeroallergens where possible in sensitized children with problematic severe asthma.

With regards to severe asthma with fungal sensitization, one randomised controlled trial in adults and case reports in children suggest a treatment response to itraconazole therapy. This treatment has the merit of being safe, although the interaction with budesonide may potentially lead to adrenal failure and must be remembered. As for ABPA, specific IgE to aspergillus may be a diagnostic clue, which needs to be considered in children with problematic severe asthma and mould sensitisation.
• **Clinical recommendation:** Skin prick testing and RAST tests should be part of the routine clinical work-up in problematic severe asthma, and allergen avoidance should be instituted for sensitized children

• **Research recommendation:** Research is needed on:
  - how to respond to discordant results between RAST and skin prick tests
  - whether analysis of multiple allergen components adds relevant information
  - the clinical efficacy of allergen avoidance
  - the frequency and optimal management of severe asthma with fungal sensitization

**Upper airways disease**

Allergic rhinitis often co-exists with asthma[^46] and upper airway disease may worsen asthma[^47]. Treatment of allergic rhinitis has been advocated as an important component of asthma management[^48][^49], but to what extent treatment of allergic rhinitis may improve asthma is controversial[^50].

Studies on sinusitis treatment in problematic severe childhood asthma are lacking. However, upper airway evaluation, including anterior rhinoscopy when appropriate, should be part of the assessment of problematic severe asthma. Additional tests including sinus CT or Magnetic Resonance Imaging (MRI), which are more informative than plain sinus X-ray studies in children, should be considered[^51][^52]. Sinusitis has been reported in a high proportion of children with severe asthma[^53] with or without nasal symptoms, and a relation between abnormalities on sinus CT and bronchial eosinophilic inflammation was shown in adults[^54][^55]. A trial of treatment for allergic rhinitis in children with problematic severe asthma would seem reasonable.
Clinical recommendation: Upper airway assessment is a routine part of the clinical assessment of problematic severe asthma. Allergic rhinitis should be treated, although the evidence that this will improve the asthma is limited.

Research recommendation: We need more work on comparisons of nasal and bronchial inflammation, and to what extent (if at all) upper airway samples reflect lower airway inflammatory phenotype.

Quality of life

Functional impairment in daily life is common in asthma. Health-related quality of life (QoL) based on reports from the child and/or parents gives different information compared to traditional clinical measurements. Overall, increasing asthma severity is associated with impaired health-related QoL, although the exact relationship has not always been clear.

We do not have sufficient information to recommend which QoL questionnaires should be used in problematic severe asthma, although it would seem sensible to recommend the use of asthma-specific QOL questionnaires, such as the Paediatric Asthma Quality of Life Questionnaire, PAQLQ and the Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ). Measures of QoL were recently found to improve phenotype discrimination in severe asthma, but the value of QoL measures in follow-up studies in severe asthma needs to be established.

Clinical recommendation: the PAQLQ and the PACQLQ should be available in the patients’ native language and be filled in as part of the assessment of problematic severe asthma. Optimal frequency of completing QOL for monitoring purposes is so far not established.

Research recommendation: more work is needed on whether QoL questionnaires developed for mild and moderate asthma are appropriate for more severe disease.
Imaging techniques

Specific imaging issues in problematic severe asthma include the exclusion of other diagnoses (Step 1) and the use of imaging as a specific, clinically useful biomarker. HRCT can be used in problematic severe asthma to study airway wall changes. Bronchial wall thickening on HRCT has been a consistent finding in children with problematic severe asthma and it may constitute an additional criterion of asthma severity. The association between bronchial wall thickening seen on HRCT scan and thickness of bronchial epithelial reticular basement membrane in bronchial biopsy seen in adult asthmatics, has not been replicated in children.

At the moment there is insufficient evidence to recommend the routine clinical use of any imaging technique in problematic severe asthma.

- **Clinical recommendation:** HRCT is not a routine investigation in the assessment of children with problematic severe asthma, and is only clinically indicated if there is diagnostic doubt

- **Research recommendation:** HRCT and other imaging modalities with safe image processing techniques specifically adapted for the use in children should be incorporated into research protocols, in order to try to determine any correlations with airway structure, treatment effects and prognosis

Co-morbidities ("Asthma plus")

Other co-morbidities are discussed elsewhere, and are an integral part of the assessment. In particular obesity can cause a non-inflammatory phenotype, and weight reduction should be encouraged. There should be a high index of suspicion for gastro-oesophageal reflux, particularly in young children.
**Environment**

Environmental assessments should include a home visit to ensure the indoor environment is optimal in relation to water damage, humidity and ventilation, mould exposure, general irritants, tobacco smoke and allergens.

Among children with difficult to treat asthma ongoing environmental allergen exposure may occur in sensitised children despite advice to the contrary, and thus contribute to the severity of asthma\(^3\). A nurse-led visit to the child’s home can thus be one important measure to evaluate the possible impact of allergy on lack of response to treatment\(^3\). Other facets of the home visit include assessments of adherence and psychosocial issues. The nurse should assess whether there is a complete set of in-date medication readily available within the home, whether the degree to which the child is supervised when taking medications is acceptable, and whether the ability to use the inhaler device is correct. The nurse should also obtain prescription records as well as preferably use objective measures to assess adherence\(^6\).

Merely collecting a prescription does not guarantee that the medication has been taken, but not collecting a prescription means non-adherence is a certainty. Finally, discussions of sensitive psychosocial issues are more likely to be informative if they take place in the home.

- **Clinical recommendation:** Where possible, a home visit and detailed assessment of the environment, adherence, and psychosocial co-morbidities should be performed.
- **Research recommendation:** The longer term value of this intervention needs to be determined. We also need to know whether repeated visits, and environmental sampling would be beneficial. We need to have better ways of assessing adherence in routine clinical practice.
STEP 3. ASSESS PATTERN OF INFLAMMATION

Airway inflammatory markers

Although inflammatory markers in sputum, exhaled air, serum and urine can be measured, they have so far not been implemented as part of the clinical management for problematic severe asthma. The justification for their use is that many children are prescribed ever-higher doses of anti-inflammatory therapies, which does not seem logical if there is no residual inflammation. Furthermore, for the future, it is likely that patterns of inflammation may determine which treatment should be offered.

Fractional exhaled nitric oxide

Fractional exhaled nitric oxide (FeNO) bears a loose relationship to eosinophilic airway inflammation. FeNO can predict eosinophil levels in bronchoalveolar lavage (BAL) and can identify persistent eosinophilic inflammation in children with steroid-resistant problematic asthma. Since steroid treatment reduces FeNO, poor compliance should be suspected if FeNO remains high despite the prescription of adequate doses of inhaled steroids. However, it would be a mistake to assume that asthmatic children who have a high FeNO are non-compliant; there are other causes, including excessive allergen exposure or steroid insensitivity. In adults, increased FeNO was recently shown to predict accelerated decline in lung function in problematic asthma. It is not clear if the same applies to children. The measurement of FeNO at different flows may allow partitioning of NO production to proximal and distal airways.

Inevitably, all children will have been prescribed inhaled corticosteroids, and the relationship between FeNO and airway eosinophilia is closest in steroid naive children. Thus, FeNO in severe problematic asthma is loosely indicative of the eosinophilic phenotype. The clinical role of FeNO in problematic severe asthma is still being determined.
Sputum

Sputum is usually obtained after induction with normal or hypertonic saline after pretreatment with a bronchodilator. The reported success rate is up to 80% in dedicated research centres, increasing with patient age and probably with asthma severity. The feasibility of repeated procedures is problematic in many children, which limits the clinical usefulness of sputum as a means to detect and monitor airway inflammation. Four different inflammatory patterns are reported: eosinophilic, neutrophilic, mixed eosinophilic and neutrophilic, and paucicellular. However, surprisingly, sputum cytology appeared to be normal in the majority of school-age children with difficult asthma, with eosinophilia in as few as 30%. The clinical usefulness of soluble sputum markers in childhood problematic severe asthma has yet to be determined.

Exhaled breath condensate (EBC)

Condensate from exhaled breath may reflect the composition of the airway lining fluid. EBC collection is feasible in children, even during acute asthma. Few if any EBC biomarkers have been validated for clinical use, and considerable methodological challenges remain. A recent study demonstrated an increased level of EBC 8-isoprostane in children with problematic asthma suggesting a role for oxidative stress in this asthma phenotype. The use of innovative “-omics” technologies, such as proteomics and metabolomics, may in the future offer great potential.

Other inflammatory markers in serum and urine of (eosinophilic) inflammation have in the past been used for asthma monitoring and management. These included eosinophilic products such as eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN, EPX), as
well as cysteinyl-leukotriene metabolites. Unfortunately, none of these markers have been shown to be valuable in the diagnosis or monitoring of asthma, or severity of the disease in the individual patient, even if associations have been found in groups of children.

- **Clinical recommendation:** Although assessment of airway inflammation seems intuitively to be desirable, there is as yet no firm evidence that it is clinically useful

- **Research recommendation:** Research protocols should incorporate where feasible
  - variable flow FeNO measurements
  - induced sputum cell counts
  - storage of induced sputum supernatant and cell pellets, and exhaled breath condensate samples in a Biobank
  - serum, DNA and urine

**Bronchoscopy**

In many Paediatric Pulmonology Centres, fiberoptic bronchoscopy with BAL, endobronchial biopsy, and bronchial brushing are performed routinely in children with problematic asthma. In addition to the macroscopic inspection of the large airways and the diagnosis of any structural defects, this allows for determination of remodelling and inflammatory responses, in particular in the proximal airways. More experience is required to determine the clinical role of these techniques.

- **Clinical recommendation:** Although bronchoscopy is widely used in some centres, there is as yet no firm evidence that it is useful. It may be indicated if the diagnosis is in doubt, or to assess structural anomalies, remodelling and inflammation in difficult cases
• **Research recommendation:** Research protocols should incorporate bronchoscopy where feasible, and establish a Biobank for storage of endobronchial biopsy, bronchoalveolar lavage fluid, and bronchial epithelial cells

**STEP 4 ASSESS STEROID RESPONSE**

Steroid response in childhood is not uniformly defined, and there is no consensus as to type of test, duration, dosage and administration form. In terms of how to conduct a steroid trial for treatment of difficult asthma in children 5-15 years, a recent study evaluated the efficacy of a single dose (in children <10 years) or multiple doses (given approximately once every four weeks to children >10 years) of intramuscular triamcinolone acetonide. The number and dose of triamcinolone was based on clinical judgement, and the total dose varied from 20 mg to 480 mg. Intramuscular triamcinolone resulted in significant improvement of a range of severity markers, and this was sustained beyond the 1-month pharmacological activity of the preparation. Thus, intramuscular triamcinolone might be a useful “short-term” therapy in difficult asthma in children, and is indicative of the potential steroid effect.

Clinical improvement in symptoms are usually reflected by an asthma control test. Several tests are available, such as the Asthma control questionnaire (ACQ) or Asthma Control Test (ACT). Inflammatory response may be assessed by distribution of cell types in sputum or by FeNO if the former is not available. However, cost-benefit, validity and possible superiority of one of these methods for assessing steroid response in children are not clear. The response criteria listed below are therefore provisional and for discussion.

**Complete response:** can be considered with an improved in ACT score of 20 or higher; bronchodilator use for symptoms less than three times a week (excluding during acute viral infection and its aftermath); normal pre-bronchodilator FEV₁ using appropriate reference
ranges (no short acting bronchodilator within 4 hours of the test); and normal cellularity of induced sputum/normal FeNO.

**Partial response:** failure to meet the criteria for full response, but a partial response in one or more criteria is present, defined as: an improvement in the ACT score of at least 5 points; bronchodilator use reduced by > 50%; FEV₁, increase by more than 12% predicted; in induced sputum a > 50% reduction in eosinophil percentage; > 50% fall in FeNO, with the same caveats as above.

**No response,** no significant change in any of these parameters.

Overall, steroid responsiveness may be considered at two levels. At the **clinical level,** patients will probably only consider they have responded to steroids if their symptoms have improved. Furthermore, some children may respond well to steroids and yet never re-gain normal lung function values. At the **research level,** to facilitate comparisons between centres, the assessment of multiple domains of steroid responsiveness is attractive.

- **Clinical recommendation:** There is no agreed definition of steroid response; probably the definition most acceptable to patients is improvement of symptoms
- **Research recommendation:** The response to a steroid trial should be recorded in terms of symptoms, spirometry, inflammatory markers, and bronchodilator response, with the ultimate aim of reaching an appropriate definition of steroid responsiveness.

**CURRENT KNOWLEDGE GAPS AND CONCLUSION**

It is clear from the above that many techniques are used in the assessment of children with problematic severe asthma, but few have been validated. This group of children is very heterogeneous, and no single centre is likely to see enough patients to be able to conduct
randomised trials or move the field forwards with pathophysiologic studies. Thus, international collaboration is essential. We suggest that this should start with a detailed evaluation of these patients, using standardised methods, which will allow for building a large cohort of carefully characterised patients. The next step is to move to more objective methods of phenotyping, such as cluster or principle component analysis, in order to define homogeneous groups of children. These groups can then be used (a) to refine testing, and see which of the many techniques we have described above is clinically useful; (b) to carry out randomised controlled trials of specific therapies in focussed groups of patients; and (c) to carry out mechanistic studies, including gene association studies, to try to unravel the question what makes this child’s asthma difficult to control, and why the child does not respond to the simple medications which are so effective in most children.

ACKNOWLEDGEMENTS

This review was initiated and financially supported by the Global Allergy and Asthma European Network GA²LEN (EU contract number FOOD-CT-2004-506378).

The PSACI group consists of the following members:

E. Baraldi and A. Barbato: Department of Pediatrics, University of Padova, School of Medicine, Padova, Italy. F.M. de Benedictis: Department of Paediatrics, Salesi Children's Hospital, Ancona, Italy. A.L. Boner, D.G. Peroni and G.L. Piacentini: Department of Pediatrics, University of Verona, Verona, Italy. A. Bush and N.M. Wilson: Department of Respiratory Paediatrics, Royal Brompton Hospital, London, UK. K.H. Carlsen: Department of Paediatrics, Oslo University Hospital, and the Faculty of Medicine, University of Oslo, Norway. J.C. De Jongste: Department of Paediatrics, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands. E. Eber: Respiratory and Allergic
Disease Division, Department of Paediatrics and Adolescence Medicine, Medical University of Graz, Graz, Austria. G. Hedlin and C. Pedroletti: Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden. K. C. Lødrup Carlsen: Department of Paediatrics, Oslo University Hospital and the Faculty of Medicine, University of Oslo, Norway. K. Malmström: Department of Allergy, Helsinki University Central Hospital, Helsinki, Finland. E. Melén: Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. R.J.M. Middelveld: The Centre for Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. N. Papadopoulos and P. Xepapadaki: Allergy Research Center, University of Athens, Athens, Greece. J. Paton: Division of Developmental Medicine, University of Glasgow, Royal Hospital for Sick Children, Glasgow, UK. S. Pedersen: University of Southern Denmark, Department of Paediatrics, Kolding Hospital, Kolding, Denmark. P. Pohunek: Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. G. Roberts: University Child Health, University of Southampton School of Medicine, Southampton, UK. G. Wennergren: Department of Paediatrics, University of Gothenburg, Queen Silvia Children's Hospital, Gothenburg, Sweden.
A step-wise assessment plan is recommended in problematic severe asthma.

**Step 1. Exclude wrong diagnosis**
Alternative diagnoses, differential diagnosis investigations

**Step 2. Full multidisciplinary assessment**
Identify “difficult to treat”

**Step 3. Assess pattern of inflammation**

**Step 4. Assess steroid response**
Exclude steroid resistance

---

- Minimum Chest X ray
- Immunoglobulins
- Sweat test

**In the patient:**
- Lung function
- Bronchial responsiveness
- Exercise limitation
- Allergy
- The impact of allergen avoidance
- Upper airways disease
- Quality of life
- Lung/airway imaging including HRCT
- Co-morbidities

**Environmental:**
- Home visit assessment (living conditions)
- Environment,
- Treatment adherence
- Psychosocial co-morbidities

**Non-invasive:**
- FeNO,
- Sputum cell counts
- Exhaled breath and breath condensate
- Biobank storage

**Invasive:**
- Fiberoptic bronchoscopy
- BAL ?

**Triamcinolone i.m. or prednisolone**
- Complete or partial response

i.m. intramuscular
References


64. Jentzsch NS, Camargos PA, Colosimo EA, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. *Allergy* 2009;64(10):1458-62.


